This test is most useful if any of these apply to you.
Candida albicans lives quietly in most healthy people. It sits on your skin, in your mouth, throughout your gut, and on other mucosal surfaces, usually in modest amounts that cause no trouble. When something tips the balance, an antibiotic course, a stretch of poor sleep and stress, a weakened immune response, this yeast can multiply and start to behave very differently.
A stool-based check for Candida albicans gives you a window into whether yeast is overgrowing in your gut, a pattern linked to digestive symptoms, recurrent mucosal infections, and broader microbiome disruption. This is an exploratory marker rather than a definitive diagnostic, and the result is most useful when interpreted alongside symptoms and the rest of your microbiome picture.
Candida albicans is a single-celled fungus that can switch between a round yeast form and a longer thread-like form (called hyphae). That shape-shifting matters: the thread-like form is what allows it to push into tissue and form sticky communities on surfaces (called biofilms) that resist both your immune system and antifungal drugs.
Its outer wall is built from layers of sugar polymers (chitin and beta-glucans) wrapped in proteins that act like grappling hooks for attaching to your cells. It also releases damaging enzymes, including secreted aspartyl proteinases, phospholipases, and a small pore-punching peptide called candidalysin, that can injure the cells lining your gut, mouth, or vagina.
Candida intestinal carriage is the rule, not the exception. In a study of nearly 700 healthy adults, the majority carried Candida albicans in the gut without overt disease. The reason that does not translate into universal infection is that healthy bacteria, intact gut lining, and a working immune system normally keep the yeast in check.
When that balance breaks, gut Candida overgrowth becomes a starting point for problems. The gut is recognized as a major source of bloodstream Candida infections, with yeast translocating across a damaged intestinal barrier into the circulation. Elevated intestinal Candida has also been observed in inflammatory bowel disease, irritable bowel syndrome, neonatal necrotizing enterocolitis, colorectal cancer, and primary sclerosing cholangitis, and Candida-related antibodies appear in both Crohn's disease and coeliac disease.
Candida albicans is the leading cause of invasive candidiasis worldwide and is listed by the World Health Organization as a critical-priority fungal pathogen. In hospitalized patients with bloodstream Candida infections, mortality is high: a multinational ICU study found mortality above 50% for C. albicans candidaemia, with rates trending even higher for non-albicans species. Most invasive cases trace back to gut colonization that crossed the intestinal barrier under conditions of immune suppression, critical illness, broad antibiotic use, or indwelling devices.
For someone who is otherwise healthy, this severe end of the spectrum is unlikely. But the underlying biology is the same: a yeast that lives quietly in the gut becomes a problem when it expands, sticks to tissue, and forms biofilms. A high stool reading is not a diagnosis of invasive disease, but it does flag that the conditions favoring overgrowth may be in place.
The same organism is responsible for several familiar conditions: oral thrush (white coating on the tongue or cheeks), vulvovaginal candidiasis (yeast infections), and skin yeast infections in moist areas. In a study of 100 women with recurrent vulvovaginal candidiasis, the Candida albicans strains isolated showed stronger biofilm formation, higher expression of virulence genes, and increased antifungal resistance compared with strains from women who were merely colonized.
Oral Candida overgrowth has its own consequences. A meta-analysis found that children with oral Candida albicans had substantially higher odds of early childhood cavities compared with children without. In a separate study of 100 patients with oral thrush, C. albicans dominated the oral fungal community and fungal diversity collapsed, a pattern consistent with overgrowth-driven disease.
Because Candida albicans is an organism rather than a hormone or protein your body makes, "high" and "low" mean colonization burden rather than a level of one of your own molecules. A low or undetectable reading is generally considered benign: many healthy people have very little detectable yeast and that is not described as a deficiency in any of the available research.
A high reading reflects increased Candida load and, often, disrupted microbial balance around it. It does not by itself prove that yeast is causing your symptoms, because a substantial fraction of healthy people also carry detectable Candida. The clinical concern rises when high yeast levels appear together with symptoms, with markers of inflammation, with reduced bacterial diversity, or in people with risk factors like recent antibiotics, immune suppression, or a diet pattern that favors yeast.
Stool Candida testing sits in the research-and-exploratory zone of lab medicine. There are no consensus reference ranges that say "this number means disease." Different labs use different methods (culture, PCR, sequencing) and report results in different units, so direct comparison between labs can be misleading. Detection thresholds vary, and a single reading captures one moment in a system that shifts day to day with diet, sleep, antibiotics, and stress.
What that means in practice: do not treat a Candida result like a cholesterol number. Treat it like one data point in a microbiome picture. A high reading earns attention; it does not by itself prescribe a course of action.
Serial measurement is more useful than a single result. Gut microbiota composition can shift meaningfully over weeks in response to antibiotics, diet, illness, and stress, and Candida abundance moves with that broader ecosystem. A single high reading might reflect a transient bloom after an antibiotic course; a persistently high reading across two or three tests months apart suggests a more durable imbalance worth investigating.
A reasonable cadence: a baseline test when you are curious or symptomatic, a retest in 3 to 6 months if you are making changes to address the result or recovering from an antibiotic course or illness, then annually as part of broader microbiome monitoring. If you are tracking response to a specific intervention, time the retest to when you would expect the gut community to have stabilized after the change, typically at least 8 to 12 weeks.
A high stool Candida reading should prompt a closer look rather than an immediate antifungal prescription. Pair it with the rest of the picture: are you having digestive symptoms, recurrent yeast infections, oral thrush, or skin yeast issues? Are inflammation markers like stool calprotectin or secretory IgA out of pattern? Is bacterial diversity reduced? Do you have a history of repeated antibiotic courses, immune suppression, or uncontrolled blood sugar?
Combinations matter more than the Candida number alone. High Candida plus high calprotectin plus symptoms is a different picture than high Candida in someone who feels fine. If results and symptoms align, a gastroenterologist or integrative practitioner familiar with microbiome testing can help decide whether to confirm with a different method, pursue antifungal treatment, or focus first on restoring bacterial balance and addressing upstream drivers. For systemic symptoms or recurrent mucosal infections, an infectious disease consultation may be appropriate.
Evidence-backed interventions that affect your Candida Species level
Candida Species is best interpreted alongside these tests.